It was concluded that GC in vivo will display a dual regulation by NO: a long-lasting tonic activity (10 -20% of maximum) due to persistent occupation by NO of the heme binding site and phasic activity due to engagement of another unidentified, lower affinity site. The hypothesis was first tested by monitoring GC activity in rat platelets maintained in vitro and exposed to calibrated NO transients. The kinetics was as expected for a single binding site for NO (EC50 ؍ 10 nM), with activation and deactivation of enzyme activity conforming to the predictions of a simple receptor model. No tonic GC activity attributable to long-term NO binding was detected after exposure to the full range of active NO concentrations (peaking at 2-500 nM). Comparable results were obtained by using neural cells isolated from the cerebellum. After exposure to high NO concentrations, persistent GC activity could be recorded, but this activity was caused artifactually by secondary NO sources being formed in the medium. The new scheme for regulation of GC activity by NO is of doubtful relevance to cells.cerebellum ͉ cyclic GMP ͉ platelet N itric oxide (NO) functions as an intercellular signaling molecule in most tissues and participates in a diverse range of phenomena, including the regulation of blood flow, neurotransmission, and the immune response (1). Although NO may engage other mechanisms, many of the physiological effects of NO are exerted through specialized receptors possessing intrinsic guanylyl cyclase (GC) activity. In this way, NO causes the accumulation of cGMP in target cells, leading to activation of one or more downstream targets, including kinases, phosphodiesterases (PDEs), and ion channels. The best characterized GC-coupled NO receptors exist as heterodimers of ␣-and -subunits. According to the conventional scheme, NO binds to a prosthetic heme group associated with the -subunit, after which the bond between the heme and a nearby histidine residue breaks, causing a conformational change that propagates to the catalytic domain, greatly speeding the conversion of GTP into cGMP (2-4). Upon the removal of NO, the receptor in cells deactivates within a few hundred milliseconds (5), although when the purified protein is used, deactivation is somewhat slower (6). Nevertheless, in both cases, the existing mechanism is analogous to classical receptor activation, in which agonist binding reversibly triggers a conformational change that transduces the signal in a way that is graded with agonist concentration (7,8).Recently, a radical revision of the mechanism of GC activation by NO in vivo has been proposed on the basis of spectroscopic and enzymatic studies of purified recombinant ␣11 protein (9). According to this hypothesis, NO remains firmly bound to the heme in the presence of physiological concentrations of ATP and GTP, resulting in a tonic level of GC activity amounting to 10-20% of the maximum. Rapidly reversible GC activity of the type that has been found in cells (5) and which is likely to underlie the transient fu...